Project code: TECH_08-A1-2008-0306
Project duration: 2008.09.01-2010.12.31
The AVINOMID anti-cancer drug discovery programme is partly supported by the „Ányos Jedlik” grant from the National Office for Research and Technology (NKTH) of the Hungarian Government.
This project is based on the observation that new thalidomide analogues, developed by the coordinator, Avidin Ltd., interfere with the lipid metabolism of tumor cells by binding to intracellular lipid droplets and the endoplasmic reticulum resulting in anticancer effects. The goal of the consortium is to exploit the therapeutic value of the patented molecule family. According to our previous results this new type of molecule family possesses significant anticancer and anti-inflammatory activities. By further optimization as well as by focusing on certain tissues (e.g. to liver or kidney), we can develop potential drugs for the treatment of malignant and inflammatory diseases. Starting from Ac-202, as a lead-like molecule we intend to synthesize more effective analogues (lead compounds with better absorption, kinetics, solubility, and efficacy). We are going to test them against mouse and human cancers in mouse and against inflammation in rats. The effects of the lead molecule will be followed by in vivo imaging system optimized during the project. By using genomics and classical preclinical tools we establish the possibility of an original compound to enter into clinical phase.